SBP solbec pharmaceuticals limited

re: skint xcel Hi Excel, Regarding your shot at management, You...

  1. 5,995 Posts.
    lightbulb Created with Sketch. 162
    re: skint xcel Hi Excel,
    Regarding your shot at management, You can check their track records at www.Solbec.com.au . Looks pretty good to me.
    What is your/his take on patients 6,7 & 16 from the phase 1 trial. Considering no other Australian company has ever seen durable responses for a drug against the advanced stage refractory metestatic cancers of their first phase 1 trial, I thought it was impressive.
    Now if you know anything about this company you will know they are commencing phase 2 trials. Once the trial begins, like the previous trial, everything is run by an independent trials doctor. These trials have narrowed the focus down to the tumor type(RCC) shown to be most sensitive to Coramsine in the previous trial. I would think it is reasonable to expect much better results from the current trial. Safety profile looks good. The need is there. Why would you encourage me to sell at this time? Below is some information that may help you understand for yourself.
    << Renal cell carcinoma (RCC) is the most
    common renal tumor with approximately 30,000 cases per year in the USA. >>
    Two new drugs have recently been approved for RCC but the survival increases are in months. The renal patient response from the Coramsine phase 1, last I read, was already over 15 months.
    <
    The FDA approved Sutent based on its ability to shrink tumors. The trial for which it was approved showed partial shrinkage of the tumors in 40% of the patients and stable disease in another 28% with progression-free survival of 8.7 months. Median survival was 16.4 months. >>
    Neither of the above new drugs are regarded as a cure. Nexavar has a great disease stabilisation rate(85%), but the disease progresses after about 6 months. The Stutent median survival figure means half of the trial patients are deceased at 16.4 months.
    Coramsine has a totally different mode of action to the above drugs, which affect the blood supply to the kidney tumour. Coramsine uses a carbohydrate binding protein, to target and gain access to the cancerous cell and rapidly destroy it. Coramsine has also shown in pre clinicals to promote an immune response to tumours, and with the use of an immune system adjuvant, to have greatly increased potency. Current trials are as a stand alone agent.
    If you can show me an Australian biotech with better prospects and a bigger up side xcel, please let me know. I am not an investment advisor, so please do your own research. All IMHO



 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.